Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | DRD1 | P21728 | 6/20 | 0.50 |
| ▸ | DRD5 | P21918 | 6/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10871080 | 0.98 | NPSR1 (1.00) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL12969652 | 0.89 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL14945587 | 0.89 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL10882588 | 0.82 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL10884112 | 0.79 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL11247615 | 0.78 | — | — | |
| SCHEMBL10880075 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL10696964 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL10605050 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D | |
| SCHEMBL7792059 | 0.76 | ADRA2C (0.61) | ADRA2AADRA2BADRA2CCYP2D6ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0278165-A2 | Use of 3-benzazepines in the treatment of benign prostatic hypertrophy | SMITHKLINE BEECHAM CORPORATION (US) | 1988-08-17 | — | — | EP | claimed |
| US-4755507-A | Method of treating benign prostatic hypertrophy | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-05 | — | — | US | claimed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | claimed |
| EP-0080779-B1 | 3-BENZAZEPINES AS ALPHA-2 ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1986-07-16 | — | — | EP | claimed |
| EP-0080012-B1 | 6-CHLORO-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE, ITS ACID ADDITION SALTS AND ITS USE AS AN INTERMEDIATE | SMITHKLINE BECKMAN CORPORATION (US) | 1986-04-09 | — | — | EP | claimed |
| US-4541954-A | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-17 | — | — | US | claimed |
| US-4465677-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-08-14 | — | — | US | claimed |
| EP-0108170-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-16 | — | — | EP | claimed |
| EP-0080779-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-08 | — | — | EP | claimed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | claimed |
| JP-61068469-A | — | — | None | — | — | JP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-20170136029-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |